Pomdoctor Reports 16.2% Net Revenue Growth in First Half of 2025
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 03 2025
0mins
Source: PRnewswire
- Revenue Growth: Pomdoctor achieved net revenue of RMB 174,469,851 in the first half of fiscal 2025, reflecting a 16.2% year-over-year increase, indicating successful market expansion amid intense competition.
- Online Pharmacy Surge: The online pharmacy segment grew by 83.2%, driving overall revenue growth and showcasing the effectiveness of the company's promotional strategies for internet hospital services and online sales.
- Cost Management: Despite rising sales and marketing expenses, Pomdoctor maintained a stable gross profit margin of 16.2%, demonstrating success in operational optimization and cost control measures.
- Successful IPO: The company completed its IPO in October 2025, raising $23,000,016, which provides additional capital for future growth and enhances the company's strategic execution capabilities.
Analyst Views on POM
About POM
PomDoctor Ltd is a holding company principally engaged in operating a online medical services platform for chronic diseases. The Company operates its businesses through two segments. The Internet Hospital segment mainly engaged in providing online follow-up consultations and online prescription renewal service to customers and also sells prescription to customers through the website and apps. The Pharmaceutical Supply Chain segment mainly engaged in pharmacy retail sales and wholesale. The Company mainly operates its businesses in the domestic market.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
